Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2008 Jul 15;18(14):4242-8. doi: 10.1016/j.bmcl.2008.05.016. Epub 2008 May 6.

Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.

Author information

1
AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA. james.janetka@astrazeneca.com

Abstract

Checkpoint kinase-1 (Chk1, CHEK1) is a Ser/Thr protein kinase that mediates the cellular response to DNA-damage. A novel class of 2-ureido thiophene carboxamide urea (TCU) Chk1 inhibitors is described. Inhibitors in this chemotype were optimized for cellular potency and selectivity over Cdk1.

PMID:
18547806
DOI:
10.1016/j.bmcl.2008.05.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center